Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation ...
Over the last weekend, Chicago played host to the 2026 edition of the Heart Rhythm Society's annual conference (HRS 2026).
Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic ventricular tachycardia (VT)Breakthrough device designation granted for use of th ...
In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.
Still Breathing', Norway's answer to 'Pitt', mixes social commentary about a healthcare system under immense pressure with ...
Forty-three cardiology and electrophysiology codes — spanning catheter ablations, coronary revascularization procedures, electrophysiologic evaluations, heart failure management techniques and ...
Medical Device Network on MSN
Adagio Medical reports positive six-month results in FULCRUM-VT trial
The trial is evaluating the vCLAS cryoablation system at 20 centres across Canada and the US.
Adagio Medical reports positive pivotal results for vCLAS Ventricular Ablation System: Laguna Hills, California Tuesday, April 28, 2026, 17:00 Hrs [IST] Adagio Medical Holdings, I ...
Military families are sounding the alarm about the presence of toxic mold in military housing. It’s an issue that has long ...
The Apple Watch captured true arrhythmia events in children more frequently than standard patch monitoring, according to ...
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation ...
Medtronic (NYSE:MDT) today announced new clinical findings supporting its Aurora EV-ICD system and OmniaSecure defibrillation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results